Clinical trials
Colorectal Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting colorectal cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,589 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06750484RecruitingPhase 2
Testing trastuzumab deruxtecan in HER2-zero breast cancer
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT06622486RecruitingPhase 1/Phase 2
EGL-001 for advanced solid tumors after immunotherapy
This trial tests a new drug called EGL-001 for people with advanced solid tumors that have already been treated with immunotherapy. The goal is to see if the drug is safe and effective against cancer that has not responded to other treatments.
DijonAges 18 years+ - NCT06384560RecruitingPhase 1/Phase 2
Triple therapy before surgery for pancreatic cancer
This trial tests a combination of chemotherapy, radiation, and immunotherapy (pembrolizumab) before surgery for pancreatic cancer that can be removed. It aims to see if this triple therapy helps shrink tumors and improve survival.
AmsterdamAges 18 years+ - NCT06241846RecruitingPhase 2
Study of YL201 for advanced prostate cancer that has spread and stopped responding to hormone therapy
This trial tests a new drug, YL201, in men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. The goal is to see if YL201 can shrink tumors or slow the cancer's growth.
Hefei, AnhuiAges 18 years+ - NCT06241781RecruitingPhase 2
Immune cells from your tumor for cervical cancer
This trial tests a new treatment using your own immune cells (called tumor-infiltrating lymphocytes) that are grown in a lab and given back to you. It is for people with cervical cancer that has come back or spread and hasn't been stopped by other treatments.
Beijing, Beijing MunicipalityAges 18–70 - NCT05978609RecruitingPhase 2
Testing cadonilimab plus chemotherapy for advanced bile duct cancer
This trial tests a new combination therapy for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. It combines a drug called cadonilimab with standard chemotherapy to see if it works better than chemotherapy alone.
Chengdu, SichuanAges 18–75 - NCT06083870RecruitingPhase 1
Oba01 for advanced lung cancer that has progressed
This trial tests a new drug called Oba01 for people with advanced non-small cell lung cancer (NSCLC) that has gotten worse after other treatments. It targets a protein called DR5 found on cancer cells.
ShanghaiAges 18–75 - NCT05925491RecruitingPhase 2
Pembrolizumab for locally advanced nasal cavity cancer
This trial tests pembrolizumab (an immune therapy) for locally advanced sinonasal cancer that can still be cured with local treatments. It aims to improve outcomes by helping your immune system better fight the tumor.
Pavia, LombardyAges 18 years+ - NCT05956639RecruitingPhase 3
Rezvilutamide with ADT and chemo: shorter versus longer treatment
This Phase 3 trial compares two lengths of rezvilutamide treatment when given with hormone therapy (ADT) and chemotherapy for men with advanced prostate cancer. It aims to find which treatment duration works best and is safest to help control the cancer.
Nanjing, JiangsuAges 18 years+ - NCT06092086RecruitingPhase 2
Lorlatinib for first-line treatment of ALK-positive lung cancer
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Guangzhou, GuangdongAges 18 years+ - NCT06031805Recruiting
Real-world study of olaparib for prostate cancer
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
AmiensAges 18 years+ - NCT05471856RecruitingPhase 1
Test different doses of cancer drugs with ezabenlimab
This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.
Los Angeles, CaliforniaAges 18 years+ - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT04859465RecruitingPhase 2
Paclitaxel plus doxorubicin for advanced, unresectable angiosarcoma
This Phase 2 trial tests a chemotherapy combination (paclitaxel and liposomal doxorubicin) for people with advanced angiosarcoma that cannot be removed by surgery. It is meant for cases where standard treatment either did not work or was too hard to tolerate, and it aims to shrink tumors and control the disease.
Guangzhou, GuangdongAges 18–70 - NCT04819243RecruitingPhase 2
Test a BRCA-targeted drug plan for advanced ER-positive breast cancer
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
Seoul, Gannam-guAges 19 years+ - NCT06730659RecruitingPhase 1
CHT101 for CD70-positive advanced solid tumors
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
TianjinAges 18–70 - NCT04216121Recruiting
Testing a focused radiation approach for limited cancer spread
This trial looks at using a targeted form of radiation (LAT, often like SBRT) for people whose lung cancer has spread in only a few places while on osimertinib. It aims to control those “limited progression” spots and help you stay on the same medicine longer.
LeuvenAges 18 years+ - NCT03772561RecruitingPhase 1
Testing AZD5363, olaparib, and durvalumab for advanced solid cancers
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
Singapore, SingaporeAges 21–99 - NCT05599412Recruiting
Tracking safety of Lorviqua in ALK-positive lung cancer
This study is collecting real-world safety information about Lorviqua (lorlatinib) in adults in Korea who have ALK-positive metastatic non-small cell lung cancer. It helps monitor side effects and safe use after the medicine is already on the market.
SeoulAges 18 years+ - NCT03851640RecruitingPhase 3
Study drug for advanced prostate cancer that kept spreading despite standard treatments
This Phase 3 study tests HC-1119 soft capsules in men with metastatic castration-resistant prostate cancer—cancer that keeps progressing even when testosterone is blocked. It aims to see whether the drug works better than expected and is safe, especially after prior treatments like abiraterone and/or docetaxel.
ShanghaiAges 18 years+ - NCT04428671RecruitingPhase 1
Cemiplimab before and after surgery for high-risk skin cancer
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
Atlanta, GeorgiaAges 18 years+ - NCT05203913RecruitingPhase 2
Bladder cancer trial adds chemo, immunotherapy, and radiation after surgery
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
RomaAges 18 years+ - NCT07671534RecruitingPhase 2
Metronomic chemotherapy with gemcitabine, mitomycin C, and thalidomide for advanced solid tumors
This trial tests a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in a low, frequent 'metronomic' schedule to treat advanced solid tumors that have already been treated. The goal is to see if this approach can slow or stop tumor growth with fewer side effects.
Santa Monica, CaliforniaAges 18 years+ - NCT06798558RecruitingPhase 2
Lu-PSMA before prostate surgery for high-risk cancer
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Colorectal Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,589 recruiting colorectal cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced Colorectal Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- Metastatic Colorectal Cancer
- Locally Advanced Rectal Cancer
- Metastatic Colorectal Cancer (CRC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.